雙子座治療公司(Gemini Treateutics，Inc.)股價周二下跌5.2%，盤中一度跌至1.62美元，最新報1.63美元。午盤，約有45,507股股票易手，較251,995股的日均成交量下跌82%。此前該股收盤價為1.72美元。
熱門資訊> 正文
雙子治療公司(納斯達克代碼：GMTX)股價下跌5.2%
2022-07-06 13:40
Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Rating)'s share price was down 5.2% on Tuesday . The stock traded as low as $1.62 and last traded at $1.63. Approximately 45,507 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 251,995 shares. The stock had previously closed at $1.72.
Separately, HC Wainwright cut Gemini Therapeutics from a "buy" rating to a "neutral" rating and dropped their price target for the company from $5.00 to $2.00 in a research report on Friday, March 11th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $6.90.
另外，在3月11日星期五的一份研究報告中，HC Wainwright將雙子座治療公司的評級從「買入」下調至「中性」，並將該公司的目標價從5.00美元下調至2.00美元。三位研究分析師對該股的評級為持有，兩位分析師對該公司股票的評級為買入。根據MarketBeat.com的數據，該股目前的共識評級為持有，共識目標價為6.90美元。
Get
到達
Gemini Therapeutics
雙子座治療公司
alerts:
警報：
The stock has a market cap of $70.46 million, a price-to-earnings ratio of -1.04 and a beta of -0.06. The company has a 50-day moving average of $1.47 and a 200-day moving average of $1.70.
該股市值為7,046萬美元，市盈率為-1.04，貝塔係數為-0.06。該公司的50日移動均線切入位在1.47美元，200日移動均線切入位在1.70美元。
Gemini Therapeutics (NASDAQ:GMTX – Get Rating) last issued its quarterly earnings results on Friday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.15). Analysts predict that Gemini Therapeutics, Inc. will post -0.6 earnings per share for the current fiscal year.
雙子座治療公司(納斯達克代碼：GMTX-GET評級)最近一次發佈季度收益報告是在5月6日星期五。該公司公佈該季度每股收益(EPS)為0.35美元，低於普遍預期的0.20美元和0.15美元。分析師預測，雙子座治療公司將公佈本財年每股收益為0.6美元。
In related news, major shareholder Braden Michael Leonard purchased 504,487 shares of the company's stock in a transaction that occurred on Monday, April 11th. The shares were purchased at an average price of $1.35 per share, for a total transaction of $681,057.45. Following the transaction, the insider now directly owns 4,604,487 shares of the company's stock, valued at approximately $6,216,057.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 12.90% of the company's stock.
在相關新聞中，大股東Braden Michael Leonard在4月11日星期一的交易中購買了504,487股該公司股票。這些股票是以每股1.35美元的平均價格購買的，總交易額為681,057.45美元。交易完成后，這位內部人士現在直接持有該公司4,604,487股股票，價值約6,216,057.45美元。這筆交易是在提交給美國證券交易委員會(Securities&Exchange Commission)的一份文件中披露的，可以通過這個超級鏈接訪問。內部人士持有該公司12.90%的股份。
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC acquired a new position in Gemini Therapeutics during the 4th quarter worth approximately $47,000. Marquette Asset Management LLC purchased a new position in shares of Gemini Therapeutics during the 1st quarter worth $92,000. Renaissance Technologies LLC lifted its stake in shares of Gemini Therapeutics by 2,850.4% during the 1st quarter. Renaissance Technologies LLC now owns 351,100 shares of the company's stock worth $488,000 after purchasing an additional 339,200 shares during the period. BlackRock Inc. raised its position in shares of Gemini Therapeutics by 3.5% in the 1st quarter. BlackRock Inc. now owns 1,300,204 shares of the company's stock worth $1,807,000 after buying an additional 43,831 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Gemini Therapeutics by 4.3% in the 3rd quarter. Geode Capital Management LLC now owns 473,735 shares of the company's stock worth $1,913,000 after buying an additional 19,540 shares during the period. Institutional investors own 74.65% of the company's stock.
對衝基金和其他機構投資者最近增持或減持了該業務的股份。AllSpring Global Investments Holdings LLC在第四季度收購了Gemini治療公司的一個新頭寸，價值約4.7萬美元。Marquette Asset Management LLC在第一季度購買了價值92,000美元的雙子治療公司新股票頭寸。復興科技有限責任公司在第一季度增持了雙子座治療公司2850.4%的股份。復興科技有限責任公司現在擁有351,100股該公司的股票，價值488,000美元，在此期間又購買了339,200股。貝萊德股份有限公司在第一季度將其在雙子座治療公司的股票持倉量提高了3.5%。貝萊德股份有限公司在此期間增持了43,831股，目前持有1,300,204股該公司股票，價值1,807,000美元。最后，Geode Capital Management LLC在第三季度將其在雙子座治療公司的股票頭寸提高了4.3%。Geode Capital Management LLC現在持有該公司473,735股股票，價值1,913,000美元，在此期間又購買了19,540股。機構投資者持有該公司74.65%的股票。
Gemini Therapeutics Company Profile (NASDAQ:GMTX)
雙子座治療公司簡介(納斯達克：格林尼治標準時間)
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Gemini治療公司是一家臨牀階段精準藥物公司，致力於開發各種治療化合物，用於治療遺傳定義的年齡相關性黃斑變性(AMD)。它的主要候選藥物是GEM103，一種重組形式的人類補體因子H蛋白，用於治療乾性AMD患者。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Gemini Therapeutics (GMTX)
- 3 Education Stocks to Enroll in This Summer
- The Institutions Get Comfortable With The Lovesac Company
- McDonald's Might Just Be The Best Recession Proof Stock
- Basset Furniture Quietly Proves Its Value
- Earnings Revisions: Why You Shouldn't Count On A Rebound In Stocks ... Yet
- 免費獲取StockNews.com關於雙子座治療(GMTX)的研究報告
- 3只教育類股將於今夏入圍
- 這些機構對Lovesac公司感到滿意
- 麥當勞可能就是最好的抗衰退股票
- Basset家俱悄然證明其價值
- 收益修正：為什麼你不應該指望股市反彈。還沒有
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《雙子座治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對雙子座治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
